Erbitux
Erbitux - General Information
Epidermal growth factor receptor binding FAB. Erbitux is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.
Pharmacology of Erbitux
Used in the treatment of colorectal cancer, Erbitux binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Erbitux competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor–alpha. Binding of Erbitux to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.
Erbitux for patients
Erbitux Interactions
A drug interaction study was performed in which ERBITUX was administered in combination with irinotecan. There was no evidence of any pharmacokinetic interactions between ERBITUX and irinotecan.
Erbitux Contraindications
None.
Additional information about Erbitux
Erbitux Indication: For treatment of metastatic colorectal cancer
Mechanism Of Action: Erbitux binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Erbitux competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Cetuximab
Synonyms: Anti EGFR; Ig gamma-1 chain C region
Drug Category: Antineoplastic Agents
Drug Type: Biotech; Approved; Investigational
Other Brand Names containing Cetuximab: Erbitux (ImClone Systems Inc); Erbitux;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: 114 hrs
Dosage Forms of Erbitux: Solution Intravenous
Chemical IUPAC Name: Humanized anti-EGF receptor (EGFr) antibody
Chemical Formula: C6484H10042N1732O2023S36
Cetuximab on Wikipedia: https://en.wikipedia.org/wiki/Cetuximab
Organisms Affected: Humans and other mammals